How should occlusion of splenic artery be prevented in the treatment of gastric varices?
Matsumoto
Akio
A
Takimoto
Kengo
K
Takemura
Toshiki
T
D001157:Arterial Occlusive Diseases / Q000139:chemically induced / Q000517:prevention & control*; D001843:Bone Cements / Q000009:adverse effects; D004659:Enbucrilate / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D004932:Esophageal and Gastric Varices / Q000188:drug therapy*; D006801:Humans; D007267:Injections; D010778:Photochemotherapy / Q000009:adverse effects*; D012307:Risk Factors; D013157:Splenic Artery; D013162:Splenic Vein / Q000601:surgery*; D014014:Tissue Adhesives / Q000008:administration & dosage / Q000009:adverse effects
D001843:Bone Cements; D014014:Tissue Adhesives; D004659:Enbucrilate